Some consequences of long-term exposure to antipsychotic drugs that increase prolactin levels were recently described, such as a greater risk of breast cancer and low-energy fractures, indicating that hyperprolactinemia needs to be monitored in these patients (Taipale et al., 2021; Solmi et al., 2022). This evidence concerns the gene PRL and hyperprolactinemia.